Table 5. DAVID analysis of pathways significantly enriched in the list of cis- and trans-regulated genes.
| KEGG id | KEGG pathway name | Genes | Genes (n) | P-value | Fold Enrichment |
| 05410 | Hypertrophic cardiomyopathy (HCM) | LAMA2, ITGA6, ITGAV, PRKAG2, IGF1, PRKAA1, PRKAA2, TTN, TGFB2 | 9 | 0.002 | 3.739 |
| 04920 | Adipocytokine signalling pathway | ACSL1, PRKAG2, PRKAA1, ACACB, PRKAA2, AGRP, IRS1, ACSL5 | 8 | 0.003 | 4.216 |
| 04960 | Aldosterone-regulated sodium reabsorption | HSD11B1, IGF1, NEDD4L, ATP1A2, IRS1 | 5 | 0.027 | 4.306 |
| 05219 | Bladder cancer | HRAS, MMP9, MDM2, CDK4, MMP1 | 5 | 0.029 | 4.204 |
| 04144 | Endocytosis | STAMBP, HRAS, DNM1L, TGFBR1, RAB22A, SH3KBP1, ADRBK2, MDM2, NEDD4L, ZFYVE20, EHD1 | 11 | 0.034 | 2.111 |
| 04910 | Insulin signalling pathway | HRAS, PPP1R3B, PRKAG2, ACACA, PRKAA1, ACACB, PRKAA2, PPP1CB, IRS1 | 9 | 0.036 | 2.354 |
| 03320 | PPAR signalling pathway | ACSL1, SCD, MMP1, FABP5, ACOX3, ACSL5 | 6 | 0.044 | 3.071 |
| 04510 | Focal adhesion | LAMA2, CAV2, HRAS, ITGA6, PDGFA, TNC, ITGAV, IGF1, COL1A1, PPP1CB, PARVB | 11 | 0.056 | 1.933 |
| 04110 | Cell cycle | YWHAZ, MAD2L1, CDC23, MDM2, CDK7, CDK4, CUL1, TGFB2 | 8 | 0.061 | 2.260 |
| 05200 | Pathways in cancer | HRAS, PDGFA, MMP9, TGFBR1, IGF1, CDK4, MMP1, TGFB2, LAMA2, CCDC6, ITGA6, ITGAV, MDM2, TPR, GSTP1 | 15 | 0.076 | 1.615 |
| 04350 | TGF-beta signalling pathway | TGFBR1, FST, ID4, BMPR1B, CUL1, TGFB2 | 6 | 0.097 | 2.435 |
In bold, pathways related to lipid and muscle metabolism and fat deposition.